Our cases

Novo Nordisk sought to define a forward-looking strategy for ESG reporting and disclosures. The goal was to benchmark industry peers and adjacent sectors, assess alignment with leading standards and frameworks, and ultimately shape a robust reporting approach that supports transparency and trust with a wide range of stakeholders.

We began by developing a best-practice ESG reporting framework grounded in existing standards and regulation, including a detailed benchmark of ESG disclosures from peers and selected leaders outside the pharmaceutical industry.

In the second phase, we facilitated discussions with Novo Nordisk to refine the company’s level of ESG ambition, identify material topics, and explore how to meet the information needs of diverse stakeholder groups, from patients and NGOs to rating agencies and the general public.

We also conducted a review of Novo Nordisk’s available data against the requirements of leading frameworks and supported the development of governance processes to strengthen ESG reporting going forward.

Our collaboration has helped Novo Nordisk take a strategic and structured approach to ESG reporting, grounded in industry benchmarks, stakeholder relevance, and future regulatory readiness.

The resulting framework and governance setup position Novo Nordisk to deliver transparent, consistent, and stakeholder-informed ESG disclosures in an increasingly complex reporting environment.